Gilead pulls back 'orphan drug' request for experimental COVID drug

The Foster City-based company had faced criticism from Sen. Bernie Sanders and others about the designation, which would carry tax benefits and expand exclusivity for its experimental COVID-19 drug.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.